Enliven Therapeutics CFO Hohl sells $231,545 in shares

On October 19, 2026, Benjamin Hohl, CFO of Enliven Therapeutics (NASDAQ:ELVN), sold 6,018 shares of the company's common stock, generating approximately $231,545. This sale occurred after exercising options to purchase an equal number of shares, as outlined in a pre-established Rule 10b5-1 trading plan signed on March 18, 2026. The shares were sold at an average price of $38.4755 per share, with prices fluctuating between $37.785 and $38.765.

Despite this sale, the stock has surged to $41.82, resulting in a 97% return over the past year for shareholders. However, InvestingPro analysis indicates the stock may be overvalued, placing it among companies on the most overvalued list. Investors can explore additional InvestingPro Tips for further insights into ELVN’s valuation and potential.

Earlier that day, Hohl increased his holdings by acquiring 6,018 shares through the exercise of stock options, costing him $89,367. The option, originally covering 185,000 shares, became vested in full as of February 13, 2025, with the remainder vesting in 36 monthly installments. As of the reported transactions, Hohl directly owns 38,000 shares of Enliven Therapeutics common stock and also holds 175,000 derivative securities, consisting of stock options and restricted stock units (RSUs).

Meanwhile, Enliven Therapeutics has seen notable progress in its upcoming clinical trials and analyst ratings. The FDA approved the design of its planned Phase 3 ENABLE-2 trial, which will assess relcobatinib (ELVN-001) in patients with chronic myeloid leukemia who are in second-line or later treatment stages. The trial aims to enroll around 450 patients and is scheduled to commence by year-end 2026.

Following this announcement, several analysts have revised their ratings and price targets for Enliven Therapeutics. Guggenheim maintained a Buy rating with a $78.00 price target, while H.C. Wainwright upgraded its price target from $65 to $73. Morgan Stanley initiated coverage with an Overweight rating and a $70.00 price target, and JPMorgan followed suit with an Overweight rating and a $75.00 price target, both highlighting ELVN-001 as a differentiated chronic-phase CML asset.

William Blair also initiated coverage with an Outperform rating, emphasizing the growing chronic myeloid leukemia market and the need for improved treatment options. These developments reflect increasing optimism among analysts regarding Enliven Therapeutics' potential in the oncology sector.